Oncology Nurse Advisor2d
Older Age Predicts Worse Survival in Patients With HCC, Comorbidity Role Unclear
Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.
Monthly Prescribing Reference1d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...
oncnursingnews2d
Amezalpat Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
Pilot helping hundreds living with liver issues
Hundreds of a people who have chronic liver disease are being helped by an NHS trust's service that helps them attend vital ...
Science Daily3d
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Taiwan News3d
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has ...